CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
2020/2021 年及以后的复发/难治性多发性骨髓瘤
英文原题：Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.
查看英文原题
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管COVID-19疫情带来挑战，多发性骨髓瘤（MM）治疗仍在取得令人振奋的进展。2020至2021年获批用于复发/难治性（RR）MM的新药包括第二种CD38单克隆抗体伊沙妥昔单抗、首个靶向BCMA的疗法及首创抗体药物偶联物（ADC）贝兰他单抗-马福多汀、首个靶向BCMA的CAR-T 细胞产品伊德卡塞（bb2121）、首创XPO-1抑制剂塞利尼索，以及首创抗肿瘤肽-药物偶联物美法仑氟苯酰胺。本文作为专题“复发/难治性多发性骨髓瘤治疗进展：新型药物、免疫疗法及其他”的导论文章，总结RRMM最新注册性试验和新兴免疫疗法，概述MM基因组学及肿瘤诱导的MM微环境变化方面的最新认识，并介绍若干基于机制、最有希望的未来治疗策略。
展开英文摘要原文
Despite the challenges imposed by the COVID-19 pandemic, exciting therapeutic progress continues to be made in MM. New drug approvals for relapsed/refractory (RR)MM in 2020/2021 include the second CD38 monoclonal antibody, isatuximab, the first BCMA-targeting therapy and first-in-class antibody-drug conjugate (ADC) belantamab mafodotin, the first BCMA-targeting CAR T cell product Idecabtagen-Vicleucel (bb2121, Ide-Cel), the first in-class XPO-1 inhibitor selinexor, as well as the first-in-class anti-tumor peptide-drug conjugate, melflufen.
The present introductory article of the Special Issue on "Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond" summarizes the most recent registration trials and emerging immunotherapies in RRMM, gives an overview on latest insights on MM genomics and on tumor-induced changes within the MM microenvironment, and presents some of the most promising rationally derived future therapeutic strategies.
论文信息
- 作者
- Podar K、Leleu X
- 第一作者单位
- Department of Internal Medicine 2, University Hospital Krems, Mitterweg 10, 3500 Krems an der Donau, Austria.Austria
- 通讯作者单位
- Department of Hematology, and CIC1402 INSERM Unit, Poitiers University Hospital, 2 Rue de la Milétrie, 86021 Poitiers, France.France
- 文献类型
- 综述
- 期刊
- Cancers2021 Oct 14
- 原文标识
- PubMed 34680303 · DOI 10.3390/cancers13205154
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →